David Portman bought LeonaBio stock
By AlphaYouPublished Form 4
Portman David J.
Reporting filer
David Portman reported buying LeonaBio, Inc. stock. Form 4 filed Oct 29, 2026 lists 2 entries.
See the price move since this trade →
- Disclosed
- Oct 29, 2026
Reported details
2 entries| Security | Owner | Date | Code | Action | Quantity | Price | Following holdings | Reporting delay | Filed terms and references |
|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Portman David J. | 2026-10-26 | P | Purchase | 3149470 | 3149.47 | 3,149,470 | 3 days | Filed terms
|
| Warrant (derivative) | Portman David J. | 2026-10-26 | P | Purchase | 5502402 | 3149.47 | 0 | 3 days | Filed terms
|
Common Stock
- Owner
- Portman David J.
- Date
- 2026-10-26
- Code
- P
- Action
- Purchase
- Quantity
- 3149470
- Price
- 3149.47
- Following holdings
- 3,149,470
- Reporting delay
- 3 days
- Filed terms and references
Filed terms
- security Title: Common Stock
- transaction Date: 2026-10-26
- deemed Execution Date: 2026-10-26
- transaction Form Type: 4
- transaction Code: P
- equity Swap Involved: 0
- transaction Timeliness:
- transaction Shares: 3149470
- transaction Price Per Share: 3149.47
- transaction Acquired Disposed Code: A
- shares Owned Following Transaction: 3149470
- direct Or Indirect Ownership: I
- nature Of Ownership: See note
Warrant (derivative)
- Owner
- Portman David J.
- Date
- 2026-10-26
- Code
- P
- Action
- Purchase
- Quantity
- 5502402
- Price
- 3149.47
- Following holdings
- 0
- Reporting delay
- 3 days
- Filed terms and references
Filed terms
- security Title: Warrant
- id: F1
- conversion Or Exercise Price: 0.001
- transaction Date: 2026-10-26
- deemed Execution Date: 2026-10-26
- transaction Form Type: 4
- transaction Code: P
- equity Swap Involved: 0
- transaction Timeliness:
- transaction Shares: 5502402
- transaction Price Per Share: 3149.47
- transaction Acquired Disposed Code: D
- exercise Date: 2026-10-26
- id: F2
- underlying Security Title: Common Stock
- underlying Security Shares: 5502402
- shares Owned Following Transaction: 0
- direct Or Indirect Ownership: I
- nature Of Ownership: See note
- id: F3
Purchases, sales, grants and option exercises are different transactions. The reported code identifies the action; it does not establish a motive.
Filing context
- Quantities and prices are shown in the units filed. No trade value is inferred from their product.
- Portman David J.: 10% owner.
- F1: The shares are held by Sermonix Pharmaceuticals, Inc. of which Dr. Portman is the Chief Executive Officer. This Form 4 is being filed to report Dr. Portman's voting control over such securities, but Dr. Portman's personal indirect beneficial ownership does not exceed 10% of the stock in the Issuer.
- F2: The Warrant does not expire.
- F3: The Warrant was held by Sermonix Pharmaceuticals, Inc. of which Dr. Portman is the Chief Executive Officer. The Warrant was exercised on October 26, 2026, in part, into 3,149,740 Common Shares of Issuer, and the balance of the Warrant was assigned to Perceptive Xentogeny Venture Fund II, LP as a distribution-in-kind pursuant to a plan of distribution to the Sermonix Pharmaceuticals equity holders. Following the partial exercise and the assignment of the remaining Warrant rights, Sermonix Pharmaceuticals holds 3,149,740 Common Shares of Issuer.
Original sources
Prepared automatically from public filing data. Report a correction.